ClinicalTrials.gg
Sign In
Status unknownNCT04415190Updated Jun 4, 2020

the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients

An observational study in Cholangiocarcinoma, sponsored by Central Hospital, Nancy, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Central Hospital, Nancy, France · Observational

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The prognosis for cholangiocarcinoma is bad. Potentially, early management by a palliative care team could increase overall survival. We will also assess whether early management by a palliative care team could impact progression-free survival, the place of death and the date of the last chemotherapy, in particular to avoid unnecessary chemotherapy cures in an imminent end of life

02

Conditions studied

  • Cholangiocarcinoma

Browse trials for

03

In context

Cholangiocarcinoma

930 studies on the registry are indexed under Cholangiocarcinoma; 292 are open to participants now.

This study's planned enrollment of 150 is below the median of 176 across 180 observational studies indexed under Cholangiocarcinoma.

Browse Cholangiocarcinoma studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 796 studies on the registry; 187 are open to participants now.

Browse Central Hospital, Nancy, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cholangiocarcinoma metastatic or locally advanced

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age> 18 years old
  • intra- or extra-hepatic CCK or histologically proven vesicular adenocarcinoma
  • Locally advanced and / or metastatic disease from the start or recurrent
  • Initial diagnosis or recurrence between 1/01/2013 and 31/12/2019

Exclusion criteria

Exclusion Criteria:

  • \<18 years old
  • death less than one week after the diagnostic
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • cholangiocarcinoma with early palliative care

    Other: early palliative care

  • cholangiocarcinoma without early palliative care

Interventions

  • Otherearly palliative care

    early palliative care

06

What researchers measure

Primary outcomes

  1. Global survival

    Global survival from the diagnosis (to the death or because of lost to follow up)

    Time frame: baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2020; primary completion for Jun 2020, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 4, 2020
StartEst.
Jun 1, 2020
Primary completionEst.
Jun 1, 2020
CompletionEst.
Dec 31, 2020
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04415190
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Anthony LOPEZ (Dr Lopez, MCU, Central Hospital, Nancy, France) — Principal investigator
First posted
Jun 4, 2020
Start date
Jun 1, 2020 (estimated)
Primary completion
Jun 1, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Jun 4, 2020

Study contacts

Anthony Lopez
Contact
a.lopez@chru-nancy.fr
0383858585
Anthony Lopez
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cholangiocarcinoma →

Other studies from this sponsor

Central Hospital, Nancy, France →

Start the discussion